COS is the most common female reproductive disorder, affecting 10-18% of women of reproductive age worldwide [1] [2] [3] [4] . The syndrome is underpinned by excessive ovarian and/or adrenal androgen secretion, oligo-anovulation and, in many cases, insulin resistance and associated metabolic derangements 2, 5, 6 . In nonpregnant women with PCOS, serum levels of AMH are two-to threefold higher than in women without polycystic ovaries or PCOS 7, 8 , and the severity of the reproductive dysfunction is positively correlated with AMH levels 9, 10 . The pathophysiology of PCOS also extends to hypothalamic neuronal dysregulation, as most PCOS individuals exhibit increased luteinizing hormone (LH) levels suggestive of high-frequency GnRH secretion 2, 11, 12 . Whether this defect is primary or secondary to other changes in PCOS remains unclear, but recent evidence has shown that GnRH-positive neurons express AMH receptors and that exogenous AMH potently increases GnRH neuron firing and GnRH release in murine living tissue explants 11 . Familial clustering and twin studies have shown that PCOS has a strong heritable component 13 . However, the mutations that have been identified so far do not account for its high prevalence in the population, implying that fetal environmental factors might play important roles in the onset of this disease 14 .
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Here we showed that AMH concentrations during pregnancy are significantly higher in women with PCOS as compared to women with no reproductive defects (unpaired two-tailed Mann-Whitney U test, P ≤ 0.0001). Using mouse models, we showed that exposure to excess AMH during gestation engaged a series of events in the dams leading to a fetal programming of the exposed offspring into exhibiting a PCOS-like reproductive and neuroendocrine phenotype in adulthood. GnRH antagonist treatment of these offspring during adulthood normalized their neuroendocrine phenotype.
Results
AMH levels during pregnancy are higher in women with PCOS than in controls. AMH levels were previously found to be low during pregnancy in women with normal fertility 15, 16 ; however, whether this is also the case for pregnant women with PCOS has never 
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Polycystic ovary syndrome (PCOS) is the main cause of female infertility worldwide and corresponds with a high degree of comorbidities and economic burden. How PCOS is passed on from one generation to the next is not clear, but it may be a developmental condition. Most women with PCOS exhibit higher levels of circulating luteinizing hormone, suggestive of heightened gonadotropin-releasing hormone (GnRH) release, and anti-Müllerian hormone (AMH) as compared to healthy women. Excess AMH in utero may affect the development of the female fetus. However, as AMH levels drop during pregnancy in women with normal fertility, it was unclear whether their levels were also elevated in pregnant women with PCOS. Here we measured AMH in a cohort of pregnant women with PCOS and control pregnant women and found that AMH is significantly more elevated in the former group versus the latter. To determine whether the elevation of AMH during pregnancy in women with PCOS is a bystander effect or a driver of the condition in the offspring, we modeled our clinical findings by treating pregnant mice with AMH and followed the neuroendocrine phenotype of their female progeny postnatally. This treatment resulted in maternal neuroendocrine-driven testosterone excess and diminished placental metabolism of testosterone to estradiol, resulting in a masculinization of the exposed female fetus and a PCOS-like reproductive and neuroendocrine phenotype in adulthood. We found that the affected females had persistently hyperactivated GnRH neurons and that GnRH antagonist treatment in the adult female offspring restored their neuroendocrine phenotype to a normal state. These findings highlight a critical role for excess prenatal AMH exposure and subsequent aberrant GnRH receptor signaling in the neuroendocrine dysfunctions of PCOS, while offering a new potential therapeutic avenue to treat the condition during adulthood.
been investigated. Here we examined AMH levels in a cohort of 63 control pregnant women and 66 pregnant subjects with PCOS at gestational weeks [16] [17] [18] [19] (Fig. 1a) . This analysis revealed significant differences in AMH median values between the two populations, with AMH being higher in pregnant PCOS subjects than in pregnant control women (Fig. 1b) . This was not attributable to differences in age between the two groups (Supplementary Table 1 ). When we analyzed this sample stratified by body mass index (BMI) and classified women as lean or obese (lean BMI ≤ 25 kg/m 2 , obese BMI ≥ 30 kg/m 2 ), we found that AMH was significantly higher in pregnant lean women with PCOS compared with the lean control group but not in obese subjects with PCOS versus obese control [16] [17] [18] [19] , and AMH concentration was measured by ELISA (enzyme-linked immunosorbent assay). b, Circulating AMH levels in control pregnant women (n = 63) and in pregnant women with PCOS (n = 66; unpaired two-tailed Mann-Whitney U test, ***P ≤ 0.0001). c, Circulating AMH levels in control pregnant women and in pregnant individuals with PCOS stratified by their BMI and classified into lean (control lean, n = 30; PCOS lean, n = 32) and obese subjects (control obese, n = 33; PCOS obese, n = 34; one-way ANOVA followed by Bonferroni post hoc test, F 3, 125 = 7.534, P = 0.0001). d, Circulating AMH levels in pregnant women with PCOS stratified by their BMI and androgen levels (PCOS lean normoandrogenic, n = 15; PCOS lean hyperandrogenic, n = 16; PCOS obese normoandrogenic, n = 16; PCOS obese hyperandrogenic, n = 18; one-way ANOVA followed by Bonferroni post hoc test, F 3,61 = 3.922, P = 0.0126). e, Circulating AMH levels in control pregnant women and in PCOS pregnant subjects stratified by their age (control 27-34 years old, n = 42; PCOS 27-34 years old, n = 43; control > 34 years old, n = 21; PCOS > 34 years old, n = 23; one-way ANOVA followed by Bonferroni post hoc test, F 3, 125 = 6.282, P = 0.0005). The horizontal line in each plot corresponds to the median value from two technical replicates. The vertical line represents the 25th-75th percentile range. *P < 0.05, **P ≤ 0.005, ***P ≤ 0.0005; n.s., not significant.
. PAMH offspring exhibited delayed vaginal opening, delayed puberty onset ( Supplementary Fig. 1a,b) , severely disrupted estrous cyclicity (oligo-anovulation; Fig. 2b,c) , and no difference in body weight ( Supplementary Fig. 1d ). PAMH mice rarely entered the preovulatory stage of the estrous cycle and displayed prolonged time in metestrus and diestrus as compared to the control female offspring (Fig. 2b,c) . Ovarian histology of PAMH animals showed abnormalities consistent with their anovulatory phenotype, with the presence of fewer postovulation corpora lutea and fewer late antral follicles as compared to control animals (Fig. 2d) . In addition, PAMH adult female mice also showed impaired fertility, as indicated by a significant delay in their first litter and fewer litters with fewer pups per litter produced over a 3-month period (Fig. 2e) .
To test whether this disruptive effect of prenatal AMH treatment is eventually mediated by GnRH binding to the GnRH receptor, we treated pregnant mice with AMH C along with a GnRH antagonist, at a concentration previously validated in animal works (cetrorelix acetate, 0.5 mg/kg/d) 11 , from E16.5 to E18.5. Cetrorelix is known to specifically saturate GnRH receptors at the level of the anterior pituitary 21, 22 , thus decreasing the GnRH-mediated release of LH and follicle-stimulating hormone (FSH), with an effect more pronounced on LH secretion 23 . Prenatal GnRH antagonist treatment prevented the appearance of reproductive defects in postnatal offspring (PAMH + GnRH antag; Fig. 2b,e) . To determine whether AMH treatment affects the levels of circulating testosterone (T) in PAMH animals, we measured the anogenital distance, which reflects androgenic impregnation, from postnatal day (P) 30 to P60 (Fig. 3a) . The PAMH female offspring displayed a significantly longer anogenital distance than control female offspring (Fig. 3a) . This phenotype was also completely reversed by the prenatal cotreatment of AMH + GnRH antag (Fig. 3a) . Accordingly, circulating T and LH levels, measured at diestrus, were markedly elevated in PAMH compared to control and PAMH + GnRH antag mice (Fig. 3b,c) . We then evaluated LH pulsatility by serial blood sampling in female diestrous mice (Fig. 3d) and found that PAMH animals had a significantly higher LH pulse frequency as compared to control and AMH + GnRH antag treatment groups (Fig. 3e,f) . This is suggestive of an alteration in the hypothalamic network activity of the offspring caused by late-gestational exposure to AMH excess.
These data show that the PAMH mouse model displays the major cardinal PCOS neuroendocrine features: hyperandrogenism, LH elevation, sporadic ovulation, and fertility defects. However, PAMH animals did not present weight alterations, indicating that this model is most representative of the lean PCOS phenotype.
We also investigated whether prenatal exposure to the AMH precursor, proprotein (proAMH; 140 kDa), would recapitulate the same PCOS-like traits observed upon injection of the bioactive form of AMH (AMH C ; 23.4 kDa). We injected pregnant mice daily with PBS (control) or with proAMH (AMH, 0.12 mg/kg/d) from E16.5 to E18.5. Phenotypic characterization of the offspring ( Supplementary  Fig. 1a-h) showed that prenatal exposure to proAMH mirrored the PCOS neuroendocrine features observed in PAMH mice.
Peripherally administered AMH acts centrally by inducing GnRH neuronal activation. To test whether peripherally administered AMH could impinge on the maternal GnRH neurons leading to their activation, we quantified the number of active GnRHpositive neurons (GnRH Fig. 2a-d ). Indeed, a single AMH injection significantly increased the total number of Fos + nuclei in the hypothalamic organum vasculosum laminae terminalis (OVLT; unpaired two-tailed Student's t test, t 8 = 14.57, P < 0.0001; Supplementary  Fig. 2a-c) , as well as the proportion of GnRH + neurons expressing c-Fos in the same regions (unpaired two-tailed Mann-Whitney U test, P < 0.05; Supplementary Fig. 2a,b,d ). Next, we studied whether blood-borne AMH could enter the maternal brain and/or the fetal brain. For this purpose, we intravenously administered fluorescently labeled bioactive AMH to E16.5 pregnant mice 2 min before killing them for analysis and subsequently harvested the brains of the dams, the placentae, and the heads of the embryos ( Supplementary  Fig. 2e-i) . Fluorescent AMH was detectable in the maternal brains at the level of the median eminence (ME), which lies outside the blood-brain barrier (BBB), where it diffused out of the fenestrated endothelial cells into the external layer of the ME and where GnRH terminals are located ( Supplementary Fig. 2f ). Three-dimensional (3D) analysis of fluorescent AMH in solvent-cleared intact placentae collected from these animals highlighted the presence of AMH in the maternal side but not in the fetal side of the placenta, indicating that AMH cannot cross the placental barrier ( Supplementary  Fig. 2h ). This was confirmed by the lack of fluorescent AMH in the sections of the corresponding embryo brains ( Supplementary  Fig. 2i ). We also verified whether cetrorelix injected i.p. could access the maternal and, eventually, the embryo brain. Dams were treated either with PBS or cetrorelix (0.5 mg/kg/d) from E16.5 to E18.5; maternal and embryo brains were harvested one day later. High-pressure liquid chromatography-high-resolution mass spectrometry (nano-HPLC-HRMS) analysis revealed the presence of cetrorelix in the brains of the injected dams as well as in the embryo brains ( Supplementary Fig. 3a,b) .
Peripheral AMH causes gestational hyperandrogenism through brain-ovarian-placental crosstalk. Since LH secretion is an indirect measurement of GnRH neuronal secretion, we measured LH in pregnant mice at the end of the vehicle (PBS), AMH, or AMH + GnRH antag treatment period (E19.5; Fig. 3g ). During pregnancy, serum LH levels are known to be almost undetectable as a consequence of the progesterone brake. Circulating LH levels were found to be five times higher in AMH-treated pregnant mice as compared to the control group (Fig. 3g) , while this increase was prevented by the prenatal co-treatment of AMH + GnRH antag (Fig. 3g) . AMH-treated pregnant females also showed significantly higher T compared to control and AMH + GnRH antag dams, Comparisons between treatment groups were performed using a Kruskal-Wallis test followed by Dunn's post hoc analysis test; ***P < 0.0001. Data were combined from three independent experiments. M/D, metestrus and diestrus, P, proestrus; E, estrus. c, Representative estrous cyclicity of 10 mice per treatment group during 16 consecutive days. d, Quantitative analysis of corpora lutea, late antral follicles, and atretic follicles in the ovaries of control (n = 7, age: P90) and PAMH mice (n = 8, age: P90; unpaired two-tailed Student's t test: corpora lutea, t 13 = 4.879, **P = 0.0003; late antral follicles, t 13 = 4.637, **P = 0.0005; atretic follicles, t 13 = 0.226, P = 0.8243, n.s. = not significant). Data are represented as mean ± s.e.m. and were combined from two independent experiments. e, Fertility tests of the adult offspring mice (P90). Mating was performed for 90 d. Control females were paired with control males (n = 7), PAMH females were paired with PAMH males (n = 7 for each sex), PAMH + GnRH antag females were paired with PAMH + GnRH antag males (n = 6 for each sex), and GnRH antag females were paired with GnRH antag males (n = 8 for each sex). Data are represented as mean ± s.e.m. (one-way ANOVA: first litter, F 3,24 = 18.14, P < 0.0001; fertility index, F 3,24 = 7.647, P = 0.0009; number of pups, F 3,24 = 24.26, P < 0.0001; followed by Tukey's multiple comparison post hoc test). *P < 0.05, **P ≤ 0.005, ***P ≤ 0.0005. Data of fertility tests were combined from two independent experiments. , n = 32; P40, n = 32; P50, n = 24; P60, n = 24), PAMH + GnRH antag mice (n = 13 per age group), and GnRH antag (n = 11 per age group) mice (one-way ANOVA: P30, F 3,65 = 108.2, P < 0.0001; P35, F 3,68 = 155, P < 0.0001; P40, F 3,68 = 234.5, P < 0.0001; P50, F 3,54 = 143.4, P < 0.0001; P60, F 3,54 = 165.4, P < 0.0001; followed by Tukey's multiple comparison post hoc test). Data were pooled from 3 independent experiments. b, Plasma testosterone concentration in adult females (P60) in diestrus: control (n = 5), PAMH mice (n = 5), and PAMH + GnRH antag (n = 5) littermates (one-way ANOVA: F 2,12 = 28.67, P < 0.0001; followed by Tukey's multiple comparison post hoc test). c, Plasma LH levels in adult (P60-P90) diestrous females (control, n = 8; PAMH, n = 10; PAMH + GnRH antag, n = 9; one-way ANOVA: F 2,24 = 257.3, ***P < 0.0001; followed by Tukey's multiple comparison post hoc test). Data in b and c were combined from two independent replicates. d, Schematic representation of tail-tip blood sampling in adult diestrous female mice (3-4 months old). e, Number of LH pulses in adult (P60) diestrous females (control, n = 8; PAMH, n = 10; PAMH + GnRH antag, n = 9; one-way ANOVA: F 2,24 = 57.06, P < 0.0001, followed by Tukey's multiple comparison post hoc test). Data were combined from three independent experiments. f, Representative graphs for LH pulsatility of three independent experiments. Asterisks indicate the number of LH pulses per 2-h interval. g, Hormone levels in trunk blood measured by ELISA at E19.5 in dams injected from E16.5 to E18.5 with PBS (vehicle; n = 9-11), AMH (n = 8-10), or AMH + GnRH antag (n = 5; one-way ANOVA: LH, F 2,22 = 11.48, P = 0.0004; testosterone, F 2,22 = 8.095, P = 0.0023; E2, F 2,14 = 31.13, P < 0.0001; progesterone, F 2,14 = 32.08, P < 0.0001; followed by Tukey's multiple comparison post hoc test). Data were pooled from at least two independent experiments. Statistical significance in a-c, e, g: *P < 0.05, **P < 0.001, ***P ≤ 0.0001. h, Real-time PCR analysis for Amhr2, Cyp191a (cytochrome P450 family 19, subfamily a, polypeptide 1), Cyp11a1 (cytochrome P450, family 11, subfamily a, polypeptide 1), and Hsd3b1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 1) mRNA in the placenta of E19.5 dams. Dams were injected i.p. from E16.5 to E18.5 with PBS (vehicle; Amhr2, n = 16; Cyp191a, n = 17; Cyp11a1, n = 12; Hsd3b1, n = 9), AMH (Amhr2, n = 16; Cyp191a, n = 11; Cyp11a1, n = 9; Hsd3b1, n = 8), or AMH + GnRH antag (Amhr2, n = 16; Cyp191a, n = 13; Cyp11a1, n = 10; Hsd3b1, n = 10; Kruskal-Wallis test followed by Dunn's post hoc analysis test). *P < 0.05, ***P < 0.0001; n.s, not significant (P > 0.05). Data were combined from three independent experiments. Throughout the figure, data are displayed as mean ± s.e.m.
which displayed very low T levels (Fig. 3g) . We next measured circulating estradiol (E2) and progesterone in those treatment groups and found lower levels of both hormones in the AMH-treated dams as compared to the vehicle-treated and AMH + GnRH antag-treated dams (Fig. 3g ). These data indicate that late-gestational exposure to high AMH was sufficient to generate heightened LH and T levels in dams and diminished E2 and progesterone concentrations in a GnRH-dependent manner.
Since the placenta expresses AMHR2 both in humans 24 and in mice (Fig. 3h) , and since high T and low E2 levels were found in AMH-treated dams (Fig. 3g) , we examined whether AMH treatment could alter aromatase expression in the murine placenta, possibly affecting the conversion of T into E2. We performed quantitative PCR for Cyp19a1, which encodes for the enzyme P450 aromatase, in the placentae harvested from pregnant mice at the end of the treatment period (Fig. 3h) . AMH treatment significantly . TH-ir neurons in the AVPV were quantified in these animal groups (n = 3 per sex and treatment; one-way ANOVA: F 2,6 = 231.1, P < 0.0001, followed by Tukey's multiple comparisons post hoc test). Numbers of AVPV TH-ir neurons are represented as means ± s.e.m. d, Representative photomicrographs of three independent experiments showing VP-ir neurons in the bed nucleus of the stria terminalis (BnST) and medial amygdala (MeA) of a male, control female, and PAMH female at P60. VP-ir neurons in BnST and MeA were quantified in these animal groups (n = 3 per sex and treatment; one-way ANOVA: BnST, F 2,6 = 185.2, P < 0.0001; MeA, F 2,6 = 351.7, P < 0.0001, followed by Tukey's multiple comparison post hoc test). Opt, optic tract. Scale bars, 50 μ m. Data are displayed as mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0001.
lowered Cyp19a1 expression as compared to the other treatment groups (Fig. 3h) . Since the GnRH antag treatment prevented the AMH-driven inhibition of Cyp19a1 (Fig. 3h) , we investigated the expression of Gnrh1, GnRH receptor (Gnrhr), and LH receptor (Lhr) transcripts in the placentae collected from those animals ( Supplementary Fig. 4 ). All genes were found to be expressed in the placenta of the different treatment groups. While expressions of Gnrh1 and Gnrhr were similar among treatment groups, Lhr expression was found to be significantly higher in the AMH-treated dams compared to control dams and to AMH + GnRH antag-treated dams (Kruskal-Wallis test followed by Dunn's post hoc analysis test, P = 0.0009; Supplementary Fig. 4 ). We next quantified placental expression of Cyp11a1 and Hsd3b1, two genes encoding key steroidogenic enzymes involved in onset of steroidogenesis and derivation of progesterone, respectively. We did not find any differences in Cyp11a1 expression among treatment groups, but we found significantly lower Hsd3b1 expression in the placentae of AMH-treated versus control and AMH + GnRH antag-treated dams (Fig. 3h) . These data show that GnRH antagonist treatment prevented the downregulation of Hsd3b1 gene expression, indicating normalization of the GnRH-LH-driven maternal steroidogenesis. As T is an anabolic hormone, we monitored whether dams increased their body weight and fat deposition as a consequence of the AMH treatment ( Supplementary Fig. 5a -c). We did not find any changes in body weight, subcutaneous fat mass, or perigonadal fat mass in E19.5 dams injected for 3 d with vehicle, AMH, or AMH + GnRH antag ( Supplementary Fig. 5a-c) .
Since progesterone and E2 are vital to placental sufficiency and both hormones were greatly diminished in AMH-treated dams, we monitored whether there were any changes in litter loss, litter size, or birth weights of pups when dams experienced diminished Cyp19a1 and Hsd3b1 expression ( Supplementary Fig. 5d-f ). We found a significant increase in the number of aborted embryos per litter and smaller litters when dams where treated with AMH as compared to vehicle-and AMH + GnRH antag-treated dams (number of aborted embryos per litter: one-way ANOVA, F 2,26 = 6.284, P = 0.0059; total number of pups per litter: one-way ANOVA, F 2,32 = 7.636, P = 0.0019; Supplementary Fig. 5d,e) . No changes in the body weights of pups at birth were detected ( Supplementary Fig. 5f ).
PAMH female offspring exhibit a masculinization of the brain.
Perinatal gonadal steroids are primarily responsible for the sexual differentiation of the brain by triggering irreversible mechanisms 25, 26 . We therefore analyzed whether the gestational AMH-dependent maternal hyperandrogenism might interfere with the establishment of brain sexual dimorphism in the offspring and contribute to the establishment of the adult PAMH phenotype. In mammals, gonadal T secretion occurs in a sexually dimorphic pattern with a male-specific neonatal T secretion (surge), which peaks in male mice during the first hours following birth (0-4 h at P0) 27, 28 . We therefore measured T levels 2 h postpartum in control males and females as well as in PAMH female pups. This showed that T was markedly elevated in both control males and newborn PAMH females as compared to the control female pups (Fig. 4a) . Notably, the neonatal T surge observed in PAMH female pups was completely prevented by the prenatal GnRH antagonist treatment (Fig. 4a) . Similarly to T, a short-lived (1-12 h postpartum) surge in circulating LH is detected exclusively in newborn males in rodent as well as in primate species 29 . We thus measured serum LH in the pups and showed that LH was significantly more elevated in control male and PAMH female pups as compared to control females (Fig. 4a) . Also in this case, the prenatal GnRH antagonist treatment prevented the LH neonatal surge of PAMH female pups (Fig. 4a) .
To investigate whether the perinatal hyperandrogenism of the PAMH females could lead to long-term consequences in the organization of those brain areas, we analyzed three highly steroid-sensitive features of well-known sexually dimorphic brain regions in adult control males (prenatal PBS-treated), control females (prenatal PBS-treated), and PAMH females ( Fig. 4b and Supplementary Fig. 6 ). The established markers of developmental androgenization were the female-dominant tyrosine hydroxylase (TH) neuron population in the anteroventral periventricular nucleus 30 and kisspeptin neuron population in the rostral periventricular area of the third ventricle of the hypothalamus 31 , and the male-dominant vasopressin expression in the bed nucleus of the stria terminalis and the medial amygdaloid nucleus 32 . As expected, we counted a higher number of TH neurons in the anteroventral periventricular nucleus of control females versus control males (Fig. 4c) , as well as a greater proportion of kisspeptin neurons in the periventricular area of the third ventricle of females versus male mice ( Supplementary Fig. 6a,b) . Notably, PAMH female mice exhibited male-like numbers of TH and kisspeptin cells in these regions (Fig. 4c and Supplementary Fig. 6a,b) . Similar signatures of androgenization were observed in the male-like vasopressin expression in the bed nucleus of the stria terminalis and medial amygdala of PAMH females that displayed higher numbers of vasopressin-immunoreactive cells than control females, but without reaching the control male values (Fig. 4d) . These results show that PAMH female offspring exhibited masculinization of both the neonatal T and LH surge, followed by marked masculinization of the sexually dimorphic brain regions that regulate reproduction.
In utero exposure to excess AMH permanently alters the GnRH neuronal afferent network and the GnRH neuronal activity in the offspring. We next aimed at determining whether the marked hormonal and morphological signatures of androgenization detected in the PAMH animals were accompanied by protracted changes in GnRH neuronal morphology and electrical activity during adult life. Using GnRH-GFP mice and 3D-reconstruction analysis, we identified increased spine density both on the soma and along the primary dendrite (over the proximal 45-μ m distance) in PAMH female mice compared with controls during diestrus (Fig. 5a-e) . We also analyzed whether this increased spine density was correlated with increased glutamatergic or GABAergic appositions. We found no significant differences in the number of appositions of vesicular glutamate transporter 2 (vGluT2)-immunoreactive puncta (associated with the primary dendrite of GnRH cells) in PAMH compared to control female mice (unpaired two-tailed Student's t test, P > 0.05; Supplementary Fig. 7a-c) . However, when we counted the vesicular GABA transporter (vGaT)-immunoreactive puncta on GnRH cell soma and proximal dendrite, we detected a significant increase in the number of vGaT appositions onto GnRH cells of PAMH compared to control diestrous mice ( Fig. 5f-h ). Although principally recognized as an inhibitory neurotransmitter in the adult brain, there is now a consensus that GABA is excitatory in adult GnRH neurons 17, 33 . To test whether the elevated hypothalamic excitatory appositions onto GnRH neurons in PAMH animals effectively translated into increased neuronal activity, we performed whole-cell current-clamp recordings of GnRH-GFP neurons in acute coronal brain slices containing the preoptic area. The recordings were done in animals killed for analysis at diestrus, when GnRH secretion into the portal circulation was low (Fig. 5i-m) . GnRH neurons from PAMH mice showed a robust, significant, threefold increase in their spontaneous action potential firing rate, as compared with controls ( Fig. 5i-k) . The average resting membrane potential and average input resistance of GnRH neurons were similar in control and PAMH mice (Fig. 5l,m) . Since input resistance and membrane capacitance did not differ significantly among groups (mean ± s.e.m.; control: 41.348 ± 5.121 pF, n = 6; PAMH: 39.893 ± 3.921 pF, n = 7; unpaired two-tailed Student's t test: P = 0.823, t = 0.229), we can assume that the change in GnRH neuronal firing in PAMH animals compared to control animals was not due to modifications of passive electrical membrane properties.
GnRH antagonist treatment of adult PAMH mice normalizes their neuroendocrine phenotype. Since our results uncovered a persistent hyperactivation of GnRH neurons in PAMH female animals, we reasoned that partially competing with natural GnRH for binding to membrane receptors on gonadotropes and thus decreasing the rate of LH and FSH release would ameliorate the PCOSlike phenotype observed in these mice. To assess this, we analyzed estrous cyclicity of adult PAMH female mice, over 90 d, before, during, and after i.p. injections of increasing doses of GnRH antagonist (0.05 mg/kg, 0.5 mg/kg, and 5 mg/kg cetrorelix acetate per injection; Fig. 6a ). We monitored daily vaginal cytology of PAMH animals throughout this time: before the beginning of the treatments, during the cetrorelix administrations, and during the recovery times (discontinuation of treatment; Fig. 6a ). As shown in Fig. 2 , PAMH mice display prolonged time in metestrus and diestrus as compared to the control female offspring (Fig. 6a) . We initially monitored estrous cyclicity and LH concentrations in PAMH mice for 12 d before the beginning of cetrorelix treatment to ascertain that the animals displayed the typical PCOS-like neuroendocrine alterations. Subsequently, to try attaining partial inhibition of GnRH receptor and normalize GnRH action on the pituitary, we injected mice i.p. every second day with cetrorelix acetate at 0.05 mg/kg for 12 d, followed by a recovery period (no treatment) and by 12 d of treatment (every second day) with cetrorelix acetate at 0.5 mg/kg (Fig. 6a) . Tail-blood samples were collected for LH measurements twice during the GnRH antagonist treatment and once during the 10-d recovery time that followed each administration period. To attain a complete blockade of GnRH receptor and suppression of LH secretion, we finally injected the same mice daily with 5 mg/kg cetrorelix acetate over 12 d (Fig. 6a) .
As expected, PAMH mice were oligo-anovulatory, displaying about 25% of completed estrous cycles during 12 d as compared to control mice (Fig. 6b) . Notably, normal estrous cyclicity was restored only when animals were injected with 0.5 mg/kg of GnRH antagonist but not with the lowest or highest doses of the antagonist (0.05 mg/kg and 5 mg/kg cetrorelix acetate; Fig. 6b ). LH concentrations were also measured in PAMH and control mice before the beginning of the treatments (cetrorelix acetate for the PAMH group and PBS for the control group), at day 2 and day 6, after the beginning of each treatment, and 4 d after the last injection (recovery time; Fig. 6c) . The time-course and dose-effect experiments showed that the high mean LH values, initially observed in PAMH mice, were normalized following the intermittent GnRH antagonist treatment at the 0.5 mg/kg dose only (Fig. 6c) . Serum LH levels in PAMH mice following the injections with the lowest dose of cetrorelix acetate (0.05 mg/kg) were found to be significantly more elevated than in control animals, whereas they were significantly suppressed when PAMH mice were treated daily with the highest dose at 5 mg/kg (Fig. 6c) . As in clinical practice, the effects of cetrorelix on LH secretion were reversible a few days after discontinuation of treatment, independently of the dosage used (Fig. 6c) .
After having identified the concentration of the GnRH antagonist that corrected the serum LH levels and estrous cyclicity in adult PCOS-like animals, further experiments used PBS or cetrorelix at 0.5 mg/kg every 48 h (Fig. 6d-h ). We found that cetrorelix treatment restored the percent of time that animals spent in each cycle stage (Fig. 6d ) when compared to control and PAMH animals (Fig. 6d) . The aberrant T and LH concentrations, and heightened LH pulsatility, typical of PAMH mice were also normalized by the intermittent cetrorelix treatment at 0.5 mg/kg (Fig. 6e-g ). Finally, the ovarian morphology of PAMH + GnRH antag mice was also restored as compared to PAMH animals, with PAMH + GnRH antag ovaries displaying more corpora lutea and antral follicles than the PAMH group (Fig. 6h) . These data show that postnatal GnRH-antagonist treatment can rescue the major PCOS-like traits of PAMH mice: oligo-anovulation, hyperandrogenism, increased LH concentrations, and LH pulsatility.
Discussion
Serum AMH levels have been shown to decrease with age both in healthy women and in women with PCOS, although they remain always two-to threefold higher and elevated until 40 years of age in subjects with PCOS 34 . On the other hand, AMH levels were previously found to be very low during pregnancy in women without decreased fertility 15, 16 , and it has been assumed that this would be also the case for PCOS individuals. Here we showed for the first time that lean pregnant women with PCOS have significantly higher circulating AMH levels than pregnant women with normal fertility.
Most women with PCOS are hyperandrogenic during pregnancy 14, 35 , yet the cause of this remains enigmatic. In this study, we found a positive relationship between AMH levels and hyperandrogenism in pregnant lean women with PCOS but not in
Fig. 5 | PAMH GnRH-GFP mice exhibit higher GnRH dendritic spine density, increased GABAergic appositions to GnRH neurons, and elevated firing frequency of GnRH neurons in adulthood. a-d, Representative projected confocal images and 3D reconstructions of three independent experiments
showing GnRH-GFP neurons from an adult (P60) female diestrous control (a, b) and a PAMH (c, d) female diestrous mouse. e, The GnRH dendritic spine density was analyzed in adult (P60) diestrous control and PAMH GnRH-GFP females. Spine density was quantified at the soma (control, n = 10 neurons from three animals; PAMH, n = 10 neurons from three animals) and each 15-µ m portion of the primary GnRH neuronal dendrite (control, n = 12 neurons from three animals; PAMH, n = 12 neurons from three animals; paired two-tailed Student's t test: soma, t 18 = 7.5434, ***P < 0.0001; 15 µ m from soma, t 22 = 9.08, ***P < 0.0001; 30 µ m from soma, t 22 = 6.92, ***P < 0.0001; 45 µ m from soma, t 22 = 5.252, ***P < 0.0001). f,g, Representative projected confocal images of three independent experiments showing a GFP-ir GnRH neuron (green) surrounded by vGaT-ir (red) puncta in an adult diestrous control mouse (f) and a PAMH female mouse (g). Points where the vGaT signal was considered to be immediately adjacent to the GnRH neuron are indicated by arrowheads. Scale bars, 50 μ m. h, Quantification of vGaT-ir puncta adjacent to GnRH neuron soma (control, n = 10 neurons from three animals; PAMH, n = 10 neurons from three animals) and along the primary GnRH neuronal dendrite is expressed as vGaT appositions per µ m (control, n = 10 neurons from three animals; PAMH, n = 10 neurons from three animals; paired two-tailed Student's t test: soma, t 18 = 16.4, ***P < 0.0001; 15 µ m from soma, t 18 = 7.341; ***P < 0.0001; 30 µ m from soma t 18 = 9.929, ***P < 0.0001; 45 µ m from soma; t 18 = 16.4, ***P < 0.0001). i-m, Spontaneous electrical activity and membrane properties of GnRH neurons recorded in acute brain slices from control and PAMH GnRH-GFP female diestrous mice. (i) Whole-cell current-clamp recording showing the typical spontaneous burst firing of a GnRH neuron from a control mouse. The bottom trace shows an expanded time scale of that recording. (j) As in i, but in a GnRH neuron from PAMH mouse. (k) Average firing rate of GnRH neurons recorded from control (n = 9 cells from 4 animals, age P90-P120) and PAMH mice (n = 8 cells from 4 animals, age P90-P120; unpaired two-tailed Student's t test: t 15 = 2.98, *P < 0.05). (l) Average resting membrane potential (RMP) of GnRH neurons recorded from control (n = 10 cells from 4 animals, age P90-P120) and PAMH mice (n = 8 cells from 4 animals, age P90-P120; two-tailed Student's t test, t 16 = 1.143, P = 0.27; n.s., not significant). (m) Average input resistance (R in ) of GnRH neurons recorded from control (n = 6 cells from 4 animals, age P90-P120) and PAMH mice (n = 7 cells from 4 animals, age P90-P120; unpaired two-tailed Student's t test, t 11 = 0.3685, P = 0.7195; n.s., not significant). Throughout, data are displayed as mean ± s.e.m. Experiments were replicated three times with comparable results.
obese PCOS subjects. It is not known whether a causal relationship between AMH and T might exist during gestation in humans. Nevertheless, our results in mice demonstrate that AMH has a programming effect, leading to gestational and perinatal hyperandrogenism and subsequent changes in the hypothalamic-pituitarygonadal axis and hormone levels of both the dams and the progeny.
We showed for the first time that peripherally injected AMH C can access the maternal brain at the level of the ME and act centrally by inducing GnRH neuronal activation. Circumventricular organs, like the ME and the OVLT, contain fenestrated endothelial cells that allow the passage of molecules below 35 kDa 36, 37 . Therefore, circulating AMH C can have direct access to GnRH dendrites and terminals, , extending outside the BBB in the OVLT 38 and the ME 37 , respectively. Blood-borne bioactive AMH is generally presumed to be the cleaved AMH C 39 , although recent studies suggest that human blood might predominantly contain proAMH and AMH N,C 40, 41 . Whether circulating AMH N,C undergoes further cleavage at the ME remains to be investigated. However, the fact that peripheral administration of either proAMH or AMH C leads to overlapping phenotypes in the offspring of treated dams supports the latter hypothesis.
Several animal models of PCOS rely on the prenatal administration of dihydrotestosterone to induce the emergence of PCOSlike traits 42, 43 . Here we have generated a new relevant PCOS mouse model, from a clinical perspective, as our model is based on an AMH-driven gestational hyperandrogenism, which is then responsible for the pathophysiological alterations leading to the acquisition of neuroendocrine and reproductive defects in the offspring. This fits well with previous studies demonstrating that gestational hyperandrogenism in monkeys, either occurring naturally or driven by T treatment, induces PCOS-like reproductive and metabolic traits in adulthood 44, 45 . Our findings highlight a pathophysiological mechanism whereby exposure to AMH excess during pregnancy leads to a cascade of alterations impacting the maternal brain, the ovaries, and the placenta. This results in strong elevations of maternal LH and T and decreases in progesterone and E2. Maternal androgenization is most likely the result of a dual action of AMH on the dams' physiology: (i) a central action exacerbating GnRH-and LH-driven ovarian steroidogenesis and (ii) an AMH-driven inhibition of Cyp19a1 and Hsd3b1 expression in the placenta, leading to an increase in T bioavailability and a drop in circulating E2 and progesterone levels, respectively ( Supplementary Fig. 8 ). Since GnRH antagonism prevents diminished placental aromatase and Hsd3b1 expression, we can speculate that these effects could be mediated by an LH and LH-receptor signaling action, alone or in combination with AMH. These findings are in line with clinical investigations, which have identified lower placental aromatase activity in women with PCOS 46 ; this might be partly attributable to elevated levels of circulating AMH. The very low progesterone and E2 levels detected in AMH-treated pregnant mice, most likely due to compromised placental function, could explain the higher incidence of aborted embryos observed in these animals as compared to controls (Supplementary Fig. 8 ). Notably, numerous clinical reports indicate that women with PCOS have an increased risk of poor pregnancy outcomes 47 and lower maternal E2 levels than women without PCOS 48 .
Here we also showed for the first time that the AMH-driven gestational hyperandrogenism triggers a masculinization of both the neonatal T and LH surge, followed by a marked masculinization of the sexually dimorphic brain regions regulating reproduction in female offspring (Supplementary Fig. 8) . Crucially, the neonatal T and LH surges of PAMH female pups were corrected by prenatal GnRH antagonist administration, indicating that the neonatal consequences of the gestational AMH treatments are programmed in utero and not neonatally.
Since GnRH neurons do not express androgen receptor or estrogen receptor-alpha (ERα ) 49 , steroid hormone receptor activation is likely to occur in upstream neuronal afferents. We indeed provide evidence indicating that prenatal and neonatal hyperandrogenism leads to increased GABAergic appositions to GnRH neurons and to a persistent GnRH neuronal hyperactivity in adulthood. The alterations in vGaT, but not in vGluT2 appositions, observed in PAMH animals, phenocopy those of PNA mice 17, 19 . This supports a modified afferent synaptic input to GnRH neurons, which includes an increased spine density associated not with glutamatergic appositions but with increased GABAergic contacts. Since GABAergic inputs are known to excite GnRH neurons 33, 50 , we can postulate that elevated excitatory innervation of GnRH neurons might be responsible for the increased GnRH-LH pulse frequency observed in PAMH adult females. Accordingly, most lean women with PCOS exhibit high-frequency LH secretion, which is suggestive of rapid GnRH pulsatility 2, 12 . This is the case for 95% of the metabolically healthy women with PCOS, but not for obese patients with PCOS [51] [52] [53] . It should be noted that PNA mice 17, 18, 54 and the PAMH animals described in this study did not present any weight alterations, indicating that these models are most representative of the Fig. 6 | Postnatal GnRH antagonist treatment of PAMH mice restores the PCOS-like neuroendocrine phenotype. a, Schematic of experimental design whereby estrous cyclicity in PAMH adult mice was analyzed during 3 months, before and after postnatal i.p. injections with 0.05, 0.5 and 5 mg/kg cetrorelix acetate. Metestrus and diestrus, M/D; estrus, E; proestrus, P. PAMH female mice (P60, n = 6) were injected i.p. for 12 d with cetrorelix acetate at 0.05 mg/kg (every second day) followed by cetrorelix acetate at 0.5 mg/kg (every second day) and finally by cetrorelix acetate at 5 mg/kg (every day). Tail-blood samples were collected for LH measurements twice before the beginning of the treatments and at days 2 and 6 of each treatment, as well as 4 d after the last injection (in the no-treatment period that followed each administration period). b, Quantitative analysis of the percent of completed estrous cycles in control (PBS-treated, n = 19), PAMH (n = 13), and PAMH mice postnatally treated with the three doses of GnRH antagonist (n = 6 per group; cetrorelix 0.05 mg/kg, cetrorelix 0.5 mg/kg, cetrorelix 5 mg/kg). The horizontal line in each scatter plot corresponds to the median value. The vertical line represents the 25th-75th percentile range. Comparisons between treatment groups were performed using Kruskal-Wallis test followed by Dunn's post hoc analysis test. Data were combined from two independent experiments. c, Time course of serum LH concentration in PAMH mice (n = 6) before the beginning of the treatment (day 0), 2 and 4 d after the first injection of each dose of cetrorelix and after discontinuation of the drug (recovery time). Control animals (P60 females, n = 3) were injected with PBS, and tail-blood was collected during the same temporal windows as for cetrorelix treatment (one-way ANOVA: before treatment, F 3,21 = 10.6, P = 0.0004; day 2, F 3,21 = 45.72, P < 0.0001; day 6, F 3,21 = 67.10, P < 0.0001, recovery, F 3,21 = 32.62, P < 0.0001; followed by Bonferroni comparison post hoc test). Error bars represent s.e.m. from two independent experiments with two technical replicates each. d, Percentage of time spent in each estrous cycle in adult mice (control or PAMH) injected for 12 d with either PBS or cetrorelix at 0.5 mg/kg every 2 d. The horizontal line in each scatter plot corresponds to the median value. The vertical line represents the 25th-75th percentile range. The percentage of time spent in each estrous cycle was quantified in control (n = 19), PAMH (n = 11), and PAMH + cetrorelix 0.5 mg/kg (n = 11) mice (age P60-P90; Kruskal-Wallis test followed by Dunn's post hoc analysis test). Data were combined from three independent experiments. e, Mean T levels measured in diestrus, at the end of the treatment time, in adult control (n = 7), PAMH (n = 5), and PAMH + cetrorelix-treated (0.5 mg/kg; n = 5) animals (one-way ANOVA: F 2,14 = 29.24, P < 0.0001, followed by Tukey's multiple comparison post hoc test). f, Mean LH levels were measured in diestrus, at the end of the treatment time, in adult (P60-P120) control mice (n = 9), PAMH (n = 16), and PAMH + cetrorelix 0.5 mg/kg (n = 11; one-way ANOVA: F 2,33 = 72.2, P < 0.0001, followed by Tukey's multiple comparison post hoc test). Data were combined from three independent experiments. g, LH pulsatility in adult (P90) diestrous females (control, n = 6; PAMH, n = 6; PAMH + cetrorelix 0.5 mg/kg, n = 6; one-way ANOVA: F 2,15 = 40.71, P < 0.0001, followed by Tukey's multiple comparison post hoc test). h, Representative photomicrographs of ovaries stained with hematoxylin-eosin from adult (P60-P90) control, PAMH, and PAMH + cetrorelix 0.5 mg/kg mice (n = 3 each group). Scale bars, 200 μ m. Right: quantitative analyses for the mean number of corpora lutea (CL) and antral follicles (AF) in each treatment group (one-way ANOVA: CL, F 2,6 = 23.38, P = 0.0015; AF, F 2,6 = 21, P = 0.002, followed by Tukey's multiple comparisons post hoc test). Values in e-h are represented as means ± s.e.m.; *P < 0.05, **P < 0.005, ***P < 0.0001; n.s., not significant (P > 0.5).
lean PCOS condition. Such findings are highly consistent with our recently improved understanding of a leaner PCOS phenotype in the general population. Indeed, studies in referral PCOS populations (studied in the clinical environment) versus medically unselected populations have suggested that patients with PCOS diagnosed in the referral setting had a greater BMI and prevalence of obesity than women with PCOS detected in the medically unselected population [55] [56] [57] . While it is clear that the weight of PAMH mice is unaffected, further study is needed to clarify whether other metabolic parameters known to be altered in hyperandrogenic lean women with PCOS 58 , such as glucose tolerance, insulin resistance, or intraabdominal fat storage, might be also altered in these animals. In this study, we showed that the prenatal co-treatment of AMH with the GnRH antagonist prevented the appearance of PCOSlike neuroendocrine traits in the offspring, suggesting a critical role for GnRH in the prenatal programming of the disease. Our nano-HPLC-HRMS analyses demonstrated that the peripherally injected cetrorelix (1.4 kDa) can access the maternal as well as the fetal brain. Notably, in rodents' ovaries, the expression of functional gonadotropin receptors starts at the end of the first week of life 59, 60 , and therefore it is not yet in place at embryonic stages during which we treated the animals with AMH + GnRH antag. This evidence, together with our data showing that recombinant AMH cannot cross the placental barrier, strongly suggest that the effect of the prenatal GnRH antagonist treatment on the prevention of PCOS-like traits acquisition in the offspring is most likely occurring through the normalization of the maternal hypothalamicpituitary-gonadal axis.
Even more strikingly, we showed that intermittent delivery of cetrorelix to adult PAMH mice, at a concentration that only partially competes with endogenous GnRH for binding to membrane receptors on gonadotropes, corrects their neuroendocrine and reproductive alterations. Given the fact that GnRH antagonists are frequently used in the clinic, with no adverse secondary effects, pharmacological antagonism aimed at tempering GnRH-LH secretion is an attractive therapeutic strategy to restore ovulation and fertility in individuals with PCOS characterized by normal body mass composition and high LH levels.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0035-5.
Study population: human patients. Blood samples were derived from the population-based Uppsala Biobank of Pregnant Women, where blood samples are collected in conjunction with routine ultrasound screening during gestational weeks [16] [17] [18] [19] . Gestational age was determined by the ultrasound-based estimated date of birth. Eligible women were 18 years or older and without blood-borne disease. In Sweden, all pregnant women are invited to a routine ultrasound examination, and approximately 97% of the pregnant population participates, therefore, the Biobank subjects likely represent a population-based sample. Invitation to participate in the Biobank is random, with 70% of respondents accepting participation, and it is estimated that the Biobank covers approximately half of the pregnant population of Uppsala County 61 . Upon inclusion, brief demographic data are collected, including ongoing chronic disorders, ongoing medication, smoking, height, and weight. Following written informed consent, a plasma sample is collected. The sample is centrifuged within 2 h and stored at -80 °C.
As of September 2013, 160 women with PCOS had donated a blood sample to the Biobank, and from these blood samples, 32 normal-weight and 34 obese women with PCOS were selected for the present study based on their age at the time of sample collection (27-39 years old). PCOS was diagnosed according to Rotterdam criteria, i.e., presence of at least two of the following criteria: (i) polycystic ovaries on transvaginal ultrasound, (ii) oligomenorrhea, and (iii) hyperandrogenism (either biochemical or clinical). Hyperandrogenism was defined as prepregnancy hyperandrogenism: either elevated testosterone or elevated free androgen index (testosterone/sex hormone binding globulin > 0.05) or prepregnancy hirsutism as judged at the time of diagnosis. All women with PCOS had normal prolactin levels and thyroid function. Based on the initial, prepregnancy, diagnostic workup, each woman was further phenotyped as hyperandrogenic PCOS (with signs of biochemical and/or clinical hyperandrogenism) or normoandrogenic PCOS. The medical records of all women with PCOS were scrutinized to ensure a correct diagnosis of PCOS and to obtain information on obstetric and perinatal outcomes.
For each woman with PCOS an age-and BMI-matched healthy control was chosen. Each control had donated blood samples during the same week as the respective subject with PCOS and was healthy according to her self-report. The medical records of the controls were reviewed to ensure than none had been diagnosed with PCOS or female factor infertility previously. Three blood samples from the controls could not be retrieved, leaving 63 healthy controls available for analysis. All women gave written informed consent for inclusion and the study has been approved by the Independent Ethical Review Board of Uppsala, Sweden.
AMH levels during pregnancy. Serum AMH levels were measured on samples stored at -80 °C using the fully automated Access Dxi sandwich immunoassay (B13127, Beckman Coulter). This assay measures proAMH and the cleaved AMH N,C complex and uses recombinant human AMH as a calibrator. The limit of quantification of the assay is 0.57 pmol/L. Its intra-and interassay imprecision is < 5%. Results are expressed in pmol/L. Animals. Timed-pregnant female wild-type C57BL/6 J (B6) (Charles River, USA) and transgenic Gnrh-Gfp 62 mice were group-housed under specific pathogen-free conditions in a temperature-controlled room (21-22 °C) with a 12-h light/dark cycle and ad libitum access to food and water. Standard diet (9.5-mm pelleted RM3, Special Diets Services, France) was given to all mice during breeding, lactation, and growth of young stock. The nutritional profile of the standard diet RM3 is as follows: protein 22.45%, fat 4.2%, fiber 4.42%, ash 8%, moisture 10%, nitrogen-free extract 50.4%; calories: 3.6 kcal/g. Mice were randomly assigned to groups at the time of purchase or weaning to minimize any potential bias. No datasets were excluded from analyses.
C57BLl/6 J Gnrh-Gfp transgenic mice have been previously characterized 62 . Animal studies were approved by the Institutional Ethics Committees of Care and Use of Experimental Animals of the University of Lille (France; ethical protocol number: APAFIS#2617-2015110517317420 v5). All experiments were performed in accordance with the guidelines for animal use specified by the European Council Directive of 22 September 2010 (2010/63/EU). The sample size, sex, and age of the animals used is specified in the text and/or figure legends.
Genotyping. Tail biopsies were used to isolate genomic DNA to identify the sex of embryos and mice at birth using Ube1 primers: Ube1 (forward), 5′ -CACCTGCACGTTGCCCTT-3′ , and Ube1 (reverse), 5′ -TGGATGGTGTGGCCAATG-3′ . Males were identified with two bands marking both X (252 bp) and Y (334 bp) chromosomes and females with a single band representing only the X chromosome at 252 bp. Gnrh-Gfp transgenic animals were genotyped as previously described Gnrh-Gfp adult females (P60-P90) were paired with males and checked for copulatory plugs, indicating day 1 of gestation. Pregnant Gnrh-Gfp dams were given either 200 μ L i.p. injections of PBS (control-treated) or 0.12 mg kg −1 /d AMHc in PBS from E16.5, E17.5, and E18.5. PAMH Gnrh-Gfp and control Gnrh-Gfp offspring were weaned, genotyped, and phenotyped during postnatal life.
Assessment of phenotype, estrous cycle, and fertility. Control, PAMH, PAMH + GnRH antag, GnRH antag, and PproAMH female offspring were weaned at P21 and checked for vaginal opening (VO) and time of first estrus. Anogenital distance (AGD) and body mass (in g) were measured at different ages during postnatal development (P30, P35, P40, P50, and P60). At VO and in adulthood (P60), vaginal smears were performed daily for 16 consecutive days (four cycles) for analysis of age of first estrus and estrous cyclicity. Vaginal cytology was analyzed under an inverted microscope to identify the specific day of the estrous cycle. The reproductive competency of these animals was determined by pairing the following mice: control females mated with untreated C57BL6J (B6) wild-type males, PAMH females mated with PAMH males, PAMH + GnRH antag females mated with PAMH + GnRH antag males, and GnRH antag females mated with GnRH antag males, for a period of 3 months. Inexperienced males and primiparous females, selected from at least three different litters, were used for the 90-d mating protocol test. Number of pups/litter, fertility index (number of litters per females over 3 months), and time to first litter (number of days to first litter after pairing) were quantified per treatment and pairing.
Postnatal GnRH antagonist treatment in PAMH mice and assessment of phenotype and hormone levels. PAMH adult female offspring were cycled for 12 d before beginning GnRH antagonist treatments. Vaginal cytology was analyzed under an inverted microscope to record the specific day of the estrous cycle. Animals were injected intraperitoneally (i.p.) with 200 μ L of a solution containing 0.01 M PBS (pH 7.4) with cetrorelix acetate at 0.05 and 0.5 mg/kg every second day, or daily with cetrorelix acetate at the dose of 5 mg/kg. Tail-blood samples were collected for LH measurements twice before the beginning of the treatments and at days 2 and 6 of each treatment, as well as 4 d after the last injection (no treatment). Estrous cyclicity was monitored every day at the same time of day for the 12 d during postnatal GnRH antagonist treatments.
Ovarian histology. Ovaries were collected from 3-to 4-month-old diestrus mice, immersion-fixed in 4% PFA solution and stored at 4 °C. Paraffin-embedded ovaries were sectioned at a thickness of 5 μ m (histology facility, University of Lille 2, France) and stained with hematoxylin-eosin (Sigma Aldrich, cat. # GHS132, HT1103128). Sections were examined throughout the ovary. Total numbers of large antral follicles (containing a single large antrum), atretic and cyst-like follicles (large fluid-filled cysts with an attenuated granulosa cell layer, dispersed theca cell layer, and an oocyte lacking connection to the granulosa cells), and corpora lutea (CL) were classified and quantified as previously reported 63 . To avoid repetitive counting, each follicle was only counted in the section where the oocyte's nucleolus was visible. Using an ocular scale, follicles were classified by diameter into preantral, large growing (200-400 μ m), and cystic follicles ( > 400 μ m). To avoid repetitive counting, CL were counted every 100 µ m by comparing the section with the preceding and following sections. CL were characterized by a central cavity filled with blood and follicular fluid remnants or by prominent polyhedral to round luteal cells.
Perfusions. Adult mice (P60-P90) were anesthetized with i.p. injections of 100 mg/ kg of ketamine-HCl and 10 mg/kg xylazine-HCl and perfused transcardially with 20 mL of saline, followed by 100 mL of 4% PFA in 0.1 M phosphate buffer (PB) (4% PFA/0.1 M PB; pH 7.6). Brains were collected, postfixed in the same fixative for 2 h at 4 °C, cryoprotected overnight in PB/sucrose 30% at 4 °C, embedded in OCT embedding medium (Tissue-Tek), and frozen and stored at -80 °C until cryosectioning.
Immunohistochemistry. Tissues were cryosectioned coronally (Leica Cryostat) at 35 μ m for free-floating immunohistochemistry (IHC). Sections were blocked in an incubation solution of Tris-buffered saline (TBS, 0.05 M, pH 7.6), 0.25% bovine serum albumin (BSA; Sigma, A9418), and 0.3% Triton X-100 (TBS-T; Sigma, T8787) with 10% normal donkey serum (NDS; D9663; Sigma) for 2 h at room temperature (RT, 20-25 °C) before incubation with the following primary antisera (depending on experiment) for 72 h at 4 °C: guinea pig anti-GnRH (EH#1018; 1:10,000) 64, 65 , a generous gift from E. Hrabovszky (Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine of the Hungarian Academy of Sciences, Budapest, Hungary), rabbit anti-GFP (Abcam ab6556; 1:1,000), mouse monoclonal anti-vGaT (Synaptic Systems #131001; 1:500), guinea pig anti-vGluT2 (Synaptic Systems #135404; 1:500), monoclonal mouse anti-TH (Millipore MAB318; 1:3,000), guinea pig anti-(Arg /d AMH C at 10:00. Ninety minutes after injection, each mouse was anaesthetized and perfused transcardially as described above (see "Perfusions"). Brains were collected, postfixed in the same fixative for 2 h at 4 °C, embedded in OCT embedding medium, frozen, and cryosectioned coronally (Leica cryostat) at 35 μ m for freefloating IHC. Sections were processed for dual-label c-Fos-GnRH IHC.
Analysis of the double-labeled tissue was undertaken by counting the number of single-labeled and dual-labeled GnRH neurons in the preoptic area (POA: OVLT), with 2-3 brain sections representing the POA counted per mouse. Sections were scanned using a 20× objective to image c-Fos
+

GnRH
+ double-positive cells for quantification. Activated neurons were identified as expressing c-Fos in the nucleus of the GnRH i.r. cell. The number of GnRH neurons co-expressing c-Fos was quantified and grouped to produce a mean percentage of the co-expression of GnRH and c-Fos in both PBS-and AMH-treated groups. The data from each mouse were then grouped to provide the median percentage ± interquartile range (IQR).
For analysis of total c-Fos-ir cells in the POA, the same sections described above were examined using a 10× objective. The total number of c-Fos + cells per POA (OVLT) section in each treatment was quantified using the particle analysis program from Fiji (NIH); the total number of c-Fos + cells in the OVLT was quantified and averaged across OVLT sections from each animal and treatment.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
All statistical analyses were performed using Prism 7 (Graphpad Software, San Diego, CA). All electrophysiological recordings were analyzed with Clampfit 10 (Molecular Devices).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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